Not exact matches
Furthermore, while the approach has shown tremendous promise in treating blood - based cancers like
leukemia, solid tumors
remain stubbornly difficult to treat with CAR T
cells.
These donor
cells also help fight off any
remaining leukemia cells, a phenomenon known as the graft - versus -
leukemia (GVL) effect.
«While it has been previously shown that ATRA's ability to degrade the
leukemia - causing fusion oncogene PML - RAR causes ATRA to stop the
leukemia stem
cells that drive APL, the underlying mechanism has
remained elusive,» says Lu.
Acute myeloid
leukemia (AML) is the leading cause of
leukemia mortality in the United States.1 Curative treatment involves intensive induction chemotherapy, before proceeding to either consolidation chemotherapy or allogeneic stem
cell transplantation based on the patient's risk for relapse.2 This approach has been employed for > 4 decades and, although most individuals achieve complete remissions with front - line therapy, 3 the majority of patients ultimately relapse with drug - resistant disease, and overall survival rates
remain disappointingly poor.4 The limited ability of many patients to tolerate the intense chemotherapy - based treatments, in particular hematological toxicity, further contributes to the poor outcomes noted in this disease.
Chemotherapy can never kill off all a person's
leukemia cells, so this sort of immunotherapy is important to teach the immune system to find and attack those
remaining blood cancer
cells, Greer said.
Many times dogs with chronic
leukemia have regular red blood
cell and platelet counts, and they
remain fairly healthy without treatment.